Impact of uPA and PAI-1 in Breast Cancer Prognosis
Author Information
Author(s): de Witte J H, Sweep C G J, Klijn J G M, Grebenschikov N, Peters H A, Look M P, van Tienoven Th H, Heuvel J J T M, van Putten W L J, Benraad Th J, Foekens J A
Primary Institution: Department of Chemical Endocrinology, University Hospital Nijmegen
Hypothesis
The study evaluates the clinical relevance of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in breast cancer patients.
Conclusion
High levels of uPA and PAI-1 in breast cancer patients are associated with increased rates of relapse and death.
Supporting Evidence
- Statistically significant correlations were found between cytosolic levels and those in pellet extracts.
- High cytosolic levels of uPA or PAI-1 were significantly associated with increased rates of relapse and death.
- Strong correlations were found between uPA and PAI-1 levels in cytosols and those measured with commercial ELISAs.
Takeaway
This study found that certain proteins in breast cancer patients can help predict how likely they are to get worse.
Methodology
The study analyzed uPA and PAI-1 levels in cytosolic and pellet extracts from breast cancer patients using enzyme-linked immunosorbent assay (ELISA).
Participant Demographics
Patients with primary breast cancer.
Statistical Information
P-Value
P < 0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website